SLC22A3 and benign prostatic hyperplasia: CTBP2 and SLC22A3 mRNA levels were reduced by 27% and 50% in prostate cancer tissues compared with BPH tissues (4.2 [IQR 2.5] v/s 2.1[IQR 1.6]; P = 0.008 for CTBP2 and 0.48 [IQR 0.75] v/s 1.01 [IQR 1.42]; P = 0.015 for SLC22A3).